Research

We believe the next generation of therapeutics will come from rethinking not just what drugs we develop, but how they are delivered. Our mission is to unlock more effective, patient-friendly approaches to treating chronic metabolic and neurological disease through advanced delivery technologies engineered at the molecular level.

Our lead platform combines nanoparticle engineering with targeted therapeutic delivery to improve speed of onset, efficacy, and tolerability compared to conventional administration methods. In preclinical models, the platform demonstrated rapid glucose response, strong weight-loss efficacy across multiple GLP-1 agonists, and meaningful reductions in gastrointestinal side effects commonly associated with existing treatments.

Beyond metabolic disease, we believe this platform has the potential to expand therapeutic access to neurological and CNS-related indications where conventional delivery approaches remain limited. By combining deep expertise in biomaterials, translational medicine, and drug delivery systems, we aim to build a new foundation for how modern therapeutics reach patients.